- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00615160
PTK/ZK in Disseminated Malignant Melanoma
Phase II Randomized, Parallel-Group Trial on PTK-ZK With or Without DTIC in Patients With Non-resectable Metastatic Malignant Melanoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, open-label, parallel-group phase II study to evaluate the efficacy and safety of PTK-ZK in the treatment of patients with metastatic malignant melanoma who do not qualify for surgical resection:
- progressive locoregionary disease not to be controlled by surgical measures
- distant metastasis other than brain metastasis not eligible for surgical resection or radiotherapy All patients will be treated with PTK-ZK 1250mg administered orally once a day for treatment cycles of 28 days. In case of unacceptable toxicity the dose can be reduced to 1000 mg and further on to 750 mg daily.
Patients in Arm B additionally receive intravenous DTIC 850mg/m² on day 1 of each cycle.
After informed consent is given by the patient a biopsy from a metastasis should be taken before the first intake of study medication and at the end of cycle 2 to specify markers of angiogenesis and MVD (Micro vessel density).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Essen, Germany, D-45122
- Dpt. of Dermatology, University of Essen
-
Frankfurt/Main, Germany, D-60590
- Dpt. of Dermatology, University of Frankfurt
-
Kiel, Germany, D-24105
- Dpt. of Dermatology; UK-SH Campus Kiel, Germany
-
Koeln, Germany, D-50937
- Dpt. of Dermatology, University of Cologne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed nonresectable metastatic melanoma Stage III or IV (AJCC 2002) including patients with unknown primary melanoma,
- Progressive disease, defined as an increase of tumour volume according to RECIST criteria, within the last 6 months,
- Fulfilling the minimum RECIST requirements for evaluation of tumor response,
- At least two cutaneous or soft tissue lesions that can be biopsised prior to and after treatment, respectively,
- Able to undergo either contrast-enhanced CT scan or contrast-enhanced MRI scan for tumor assessment,
- Life expectancy greater than 3 months,
- ECOG performance status <2,
- Age > 18 years,
- Able to swallow and retain intact investigational drug tablets,
- Willingness and ability to adhere to the study requirements as outlined in the protocol,
- Agreement to use a highly effective method of birth control throughout the study period and 3 months thereafter for sexually active males and females of childbearing potential. Barrier contraceptives must be used throughout the trial. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study.
- Able to provide informed consent.
Exclusion Criteria:
- One or more previous systemic therapies for metastatic melanoma, excluding prior systemic therapy given for high-risk primary tumor, lymph node metastasis, or other regional (AJCC stage III) disease spread as postoperative adjuvant therapy.
- Anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy, and hormone therapy) delivered within 4 weeks prior to the 1st dose of study drug, and 2 weeks prior for palliative "spot" radiotherapy to bone metastases),
- History of uveal melanoma,
- Female patients who are pregnant or breast feeding. Women of childbearing potential must have a negative serum pregnancy test 48 hours prior to administration of study treatment.
- Impaired organ and bone marrow function defined as one or more of the following:
- Absolute neutrophil count (ANC) <1,500/µl,
- Platelets <100,000/µl,
- Total bilirubin >1.5 x ULN,
- ASAT (SGOT)/ALAT (SGPT) > 3x ULN (5x if liver metastases are present)
- History or presence of central nervous system (CNS) disease (i.e., primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis)
- Another malignancy in the 5 years prior to enrollment other than non melanoma skin cancer, or cervix carcinoma in situ,
- Major Surgery < 10 days prior to the start of study treatment
- Inadequate recovery from previous surgery, radiation, chemo-, biologic or immunotherapy
- Ongoing effects from previous investigational drug studies or concomitant participation in other investigational drug studies
- Prior use of PTK-ZK or other VGEF receptor antagonists,
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PTK-ZK, or patients who have known hypersensitivity to the study medication
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK/ZK (i.e., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the tablets).
- Myocardial infarction ≤ 6 months prior to randomization
- Acute or chronic liver disease (i.e., hepatitis, cirrhosis)
- Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen
- Chronic renal disease, i.e. Creatinine >1.5 x upper limit of normal (ULN) OR Proteinuria based on dip stick reading positive > +1 OR if the dip stick result is +1, total urinary protein > 500 mg and measured creatinine clearance < 50 ml/min from a 24-hour urine collection Haemoglobin < 9 g/dL (patients may be transfused to achieve Hb > 9 g/dL)
Other uncontrolled concomitant condition, including but not limited to:
- ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, serious uncontrolled cardiac arrhythmia, uncontrolled diabetes, seizure disorder
- Psychiatric illness/social situations that would limit compliance with study requirements, or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study
- Human immunodeficiency virus (HIV) infection,
- Prior enrollment into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
|
PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
|
Experimental: B
combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
|
PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
Dacarbazine 850 mg/m² on day 1 q4w
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response defined by RECIST criteria
Time Frame: 8 week response rate
|
8 week response rate
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity and safety
Time Frame: continuously
|
continuously
|
Tumor control as defined by the number of patients with objective tumor response or tumor stabilization according to RECIST criteria
Time Frame: Best response during time of treatment
|
Best response during time of treatment
|
Time to progression
Time Frame: Time of progression
|
Time of progression
|
Quality of life (EORTC QLQ C30)
Time Frame: During active treatment
|
During active treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael Weichenthal, MD, UK-SH Department of Dermatology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Protein Kinase Inhibitors
- Dacarbazine
- Vatalanib
Other Study ID Numbers
- UKSH A-105
- EudraCT No. 2005-002192-32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on PTK787/ZK 222584
-
David Rizzieri, MDNovartis PharmaceuticalsTerminatedLymphoma, Large-Cell, DiffuseUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedMalignant MesotheliomaUnited States
-
George Albert FisherNovartisCompleted
-
Northwestern UniversityNovartisCompletedSarcoma | Brain and Central Nervous System TumorsUnited States
-
Novartis PharmaceuticalsCompletedVon Hippel-Lindau Disease | Retinal Hemangioblastoma | CNS HemangioblastomaUnited States
-
NovartisBayerCompletedNeoplasm Metastasis | TumorsUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedMyelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
NovartisBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsBelgium, Germany, Italy, United States, Taiwan, Switzerland, Spain, Canada, Slovakia, United Kingdom, New Zealand, Australia, Portugal, Brazil, Hungary, Czechia, France, Netherlands, Sweden
-
BayerCompletedNon Small Cell Lung CancerFrance, Germany
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong